Q4 EPS Estimate for Corcept Therapeutics Raised by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research increased their Q4 2025 earnings estimates for shares of Corcept Therapeutics in a report released on Tuesday, January 21st. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $0.54 per share for the quarter, up from their previous estimate of $0.53. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2026 earnings at $0.73 EPS, Q4 2026 earnings at $0.73 EPS and FY2026 earnings at $2.47 EPS.

A number of other research firms also recently weighed in on CORT. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Corcept Therapeutics in a research report on Thursday, October 31st. StockNews.com downgraded shares of Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Finally, Truist Financial lifted their price target on shares of Corcept Therapeutics from $65.00 to $76.00 and gave the company a “buy” rating in a research report on Monday, September 30th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Corcept Therapeutics has an average rating of “Buy” and an average target price of $65.25.

Corcept Therapeutics Stock Performance

CORT opened at $62.29 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The business has a fifty day simple moving average of $54.85 and a 200 day simple moving average of $45.44. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $62.98. The company has a market capitalization of $6.53 billion, a PE ratio of 49.44 and a beta of 0.56.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. The company had revenue of $182.55 million during the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.28 earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Capital Performance Advisors LLP acquired a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at approximately $25,000. Kathleen S. Wright Associates Inc. acquired a new stake in Corcept Therapeutics in the third quarter valued at approximately $36,000. USA Financial Formulas bought a new stake in shares of Corcept Therapeutics during the fourth quarter worth $54,000. GAMMA Investing LLC increased its holdings in shares of Corcept Therapeutics by 85.4% during the third quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company’s stock worth $115,000 after buying an additional 1,147 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 496 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Activity

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider William Guyer sold 6,606 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $48.97, for a total value of $323,495.82. Following the sale, the insider now owns 5,796 shares of the company’s stock, valued at approximately $283,830.12. This represents a 53.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,011 shares of company stock worth $1,951,268. 20.50% of the stock is currently owned by corporate insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.